Antibodies positive for P.1 variants in LTC residents

Published Date: 16 Feb 2023

How is the SARS-CoV-2 mRNA antibody similar to the P.1 gamma strain and other strains?

Read Full News

Latest News

Buridan’s Ass and the Limits of Medical Reasoning

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

AI Tool Shows Promise for Lung Cancer Response Assessment

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

9/11-Related Cancers Still Emerging 25 Years Later

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

FDA OKs First Drug to Target Muscle Loss in SMA

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Admin Hurdles, Not Insurance, Block Bariatric Surgery Access

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Acute Otitis Media: The Cost of a Common Childhood Infection

Dr. Pichichero discusses the financial and health costs of acute otitis media.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Dr. Pichichero discusses the financial and health costs of acute otitis media.

News All Time

Disparities in Urban and Rural Mortality from Non-Melanoma Skin Cancers

This study assessed differences in age-adjusted mortality rates in nonmelanoma skin cancer in U.S. urban and rural populations.

Improving Resident Attitudes Toward Patients with SCA

This study evaluated whether a CAB-designed educational intervention could improve resident physician attitudes toward patients with SCA.

Does This New Clue Explain the Smoking-Parkinson’s Mystery?

Carbon monoxide may help explain the long-observed but perplexing association between smoking and a lower risk for Parkinson’s disease.

Cancer Screening Lower for Adults With Disabilities

A new study finds millions of adults with disabilities are missing critical cancer screenings, but those with disabilities have higher rates of at-home stool testing for colorectal cancer.

Early Remdesivir May Protect Kidney Grafts After COVID

Early antiviral intervention is associated with lower risks for graft loss and cardiovascular events in kidney transplant recipients with COVID.

The Future of Oncology Clinical Pathways in VHA

VA oncology Clinical Pathways logged 26,613 entries for 11,835 patients in FY25, standardizing care and paving the way to Oracle Health EHR.

Normal, but Not Optimal: Rethinking Perimenopause

In this roundtable, Drs Rachel Rubin, Makeba Williams, and Anna Cabeca discuss the changing landscape of perimenopause care — and why every clinician should join the conversation.

Inflammation on Imaging May Help Predict Hand OA Progression

Synovitis detected using ultrasonography and MRI is associated with increased odds of structural worsening in thumb base and finger joints in patients with hand osteoarthritis.

Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma

Researchers examine the roles of allogeneic and autologous HSCT in patients with hepatosplenic T-cell lymphoma and identify factors linked to survival after transplantation.

Insomnia Diagnoses, Rx Surge in Catalan Primary Care

Insomnia diagnoses and related pharmacologic prescriptions show a rise among adults in Central Catalonia; those with insomnia and polypharmacy are more likely to receive pharmacologic treatment.

Cenobamate May Offer Benefits in Rare Childhood Epilepsy

Cenobamate is linked to sustained seizure control and higher treatment retention rates over 12 months in children with developmental and epileptic encephalopathies.

Can Antiviral PEP Protect Workers During Ebola Outbreaks?

Rapid delivery of antiviral post-exposure prophylaxis at high coverage could substantially reduce deaths among healthcare workers during orthoebolavirus outbreaks, a modeling study suggests.

SMC Extends SMA Drug Access to Newborns

The Scottish Medicines Consortium extends nusinersen access to pre-symptomatic 5q SMA infants after trial data showed most learned to walk.

Vaccines Worked for Decades: Why Are Diseases Returning?

Measles, diphtheria, and polio are reappearing in places where vaccination once kept them at bay, raising concerns about declining coverage and immunity gaps.

A Novel Virtual Culinary Program for Veterans With Cancer

A single virtual cooking class helped veterans in oncology care manage appetite loss and weight change, with 9.3/10 satisfaction in this VA pilot.

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

Recommended News For You

PSA Testing Is Not Enough for Another Candidate for Prostate Cancer Screening.

Study Linking Fruits, Veggies to Lung Cancer Raises Eyebrows

Talquetamab Regimens Boost Survival in Multiple Myeloma

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

Medical Journal March 28, 2023

Short-course radiation matches standard therapy for endometrial cancer

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Recommended Articles For You

The Importance of Corrected Calcium Levels in Managing Health Conditions  

Clinical Pharmacology of Ferroptosis-Modulating Anticancer Pharmacotherapy 

Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights 

Clinical Perspectives in Oncology for Better Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More cancer cases in areas where incarceration rates are high: Study

2.

Dasatinib Fails to Improve Outcomes in CBF-AML

3.

Housing aid linked to lower medical financial hardship among US renters with cancer

4.

Including Isatuximab with a Standard Backbone Enhances Multiple Myeloma Results.

5.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

1.

Integrated Trends in Hematology for Modern Medicine

2.

Understanding the Importance of CA125: A Comprehensive Guide 

3.

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%

4.

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy

5.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Common Cancer Myths Debunked

2.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

4.

Oropharyngeal Cancer in Relation to HPV Status

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot